Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q4 FY2026 Earnings Presentation
34 slides from Piramal Pharma's earnings presentation, April 2026
Slide 1: Q4FY26 Results
QAFY26 Results Piramal April 2026 Pharma Limited
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner,
Slide 3: Piramal Pharma – A Diversified Global Pharma & Wellness Company
Piramal Pharma – A Diversified Global Pharma & Wellness Company A Portfolio of Differentiated Products and Services, and Commercial Presence in 100+ Countries CDMO Business Complex Hospital Generics Business Consumer Healthcare Business Integrated CDMO Company A Critical Care Company Consumer Health
Slide 4: Global Footprint with a Diversified Revenue Base
Global Footprint with a Diversified Revenue Base 17 100+ ~500 6,000+ Manufacturing and Countries with CDMO customers CHG customers development sites1 commercial presence (Hospitals) Total FY26 Revenue by Geography Total FY26 Revenue by Segments Others 11% North Piramal Consumer Healthcare America 14
Slide 5: AbbVie Therapeutics India Pvt. Ltd. - JV between AbbVie & PPL
AbbVie Therapeutics India Pvt. Ltd. - JV between AbbVie & PPL One of the market leaders in Indian ophthalmology segment CDMO business supplies ophthalmology products to the JV Ownership Ownership 49% 51% In FY2026, the JV reported revenue of ₹ 526 Cr. with PAT margin of 23% Brand Lumigan Combigan Re
Slide 6: Performance Highlights
Performance Highlights
Slide 7: FY26 a Transitional Year, Expect Return to Growth in FY27
FY26 a Transitional Year, Expect Return to Growth in FY27 FY26 was a transitional year, shaped by external disruptions and certain business- specific factors. Despite these challenges, we exit the year on a stronger note, with clear momentum across all our businesses. The meaningful recovery in biop
Slide 8: Performance Highlights for Q4 and FY26
Performance Highlights for Q4 and FY26 Revenue from Operations EBITDA & EBITDA Margin Performance Highlights (In ₹ Crore) (EBITDA: In ₹ Crore) EBITDA Margin ❖ Revenue - Ended FY26 on a strong note with healthy double-digit revenue growth in Q4, 0% 22% 18% adjusted for destocking in one large on-pate
Slide 9: CDMO: Laying the Groundwork for a Stronger FY27 and Beyond
Laying the Groundwork for a Stronger FY27 and Beyond Despite a Challenging Year, We Continue to Build on Our Strengths for a Stronger Future Investing In High Growth Enhanced our Strengthened Execution Continued Focus on Areas Commercial Team Across Network Quality & Sustainability CDMO Investing US
Slide 10: Laying the Groundwork for a Stronger FY27 and Beyond PCH
Laying the Groundwork for a Stronger FY27 and Beyond Despite a Challenging Year, We Continue to Build on Our Strengths for a Stronger Future Continue to Invest in Expanding E-commerce Expansion of Power Brands Profitability Distribution Network Strong growth rate of over 20% in Expansion of E-commer
Slide 11: Business Wise Performance
Business Wise Performance
Slide 12: CDMO Business
CDMO Business Expect Return to Growth with EBITDA Margin Expansion Revenue Performance (In ₹ Crore) ❖ Witnessing Improved RFP and Order In-flows Since October 2025 (10)% (4)% • Healthy traction in RFPs and order inflows in H2FY26 driven by stronger US biopharma funding (up YoY 75% in H2FY26, 30% in
Slide 13: CDMO Business
CDMO Business ❖ Advancing Development Pipeline will Unlock On-patent Commercial Manufacturing Opportunities • 155+ molecules under development, with 25 molecules in Phase 3. ❖ Strengthened our Execution - Customer Satisfaction Score Above Industry Average • Execution improved meaningfully, with stro
Slide 14: Deep Pipeline to Fuel On-Patent Manufacturing Opportunities
Deep Pipeline to Fuel On-Patent Manufacturing Opportunities Revenue by Services Building Development Pipeline Across Clinical Phases Pre-clinical, 0.4% Pre-Clinical Phase I Phase II Phase III Others1, 16% 2% 47% Phase I, 3.0x 157 33% Innovation 27% FY26 related Development work 18% Revenue by 25 2.5
Slide 15: Diversified Customer Mix – Traction with Large Pharma & New Clients
Diversified Customer Mix – Traction with Large Pharma & New Clients Customer Mix Customer Revenue Concentration Generics #1 27% 65% of revenue from Big 6% #2 Over 500 customers Pharma and Emerging 5% across segments Biopharma #3 Others 4% Big Pharma 63% #4 32% 4% Others 8% Top 5-10 17% Emerging Biop
Slide 16: Focus on Differentiated Offerings with Limited Competition
Focus on Differentiated Offerings with Limited Competition Revenue (US$Mn) from Contribution of Differentiated Offerings Differentiated Offerings to CDMO Revenue Potent sterile Peptide injectables High Potent On-patent API Differentiated API development and Offerings manufacturing (HPAPI) 44% 40% 25
Slide 17: 20+ Years Supporting Clients in the ADC Space
20+ Years Supporting Clients in the ADC Space Our Grangemouth facility is the world’s 1st USFDA approved commercial ADC CDMO Our ADC Credentials site and has completed 1,500+ ADC batches • HPAPI (from OEL ≥ ~US$64Mn • Broad bioconjugations FY26 Revenue from ADC services 10ngm3) expertise (ADCs, radi
Slide 18: Global Manufacturing Footprint and Integrated Offerings
Global Manufacturing Footprint and Integrated Offerings UK / Europe 2 Facilities 5. Grangemouth 6. Morpeth 5 6 Total 15 Facilities 4 1 2 India 9 Facilities 3 7. Ahmedabad1 8. Rabale 9. Turbhe 10. Mahad 7 14 11. Digwal 12. Hyderabad2 8 North America 4 Facilities 10 9 11 13. Ennore 14. Pithampur 1. Au
Slide 19: Maintaining our Best-in-Class Quality Track Record
Maintaining our Best-in-Class Quality Track Record 400+ Regulatory Inspections with no OAI Annual Customer Audits Highest ever customer Regulatory Inspections (Ex US FDA) US FDA Inspections audits in a year, up 27% 209 44 197 38 167 163 172 165 2 35 36 36 36 157 148 140 141 26 25 27 29 29 4 4 2 3 11
Slide 20: US Expansion on Track – Seeing Good Customer Interest
US Expansion on Track – Seeing Good Customer Interest Steadily Increasing our Footprint in the US US$90Mn investment to expand Lexington and Riverview facilities, on Our Presence in the US track. Seeing good customer interest for our North America (NA) sites. Our NA sites with differentiated capabil
Slide 21: Complex Hospital Generics Business
Complex Hospital Generics Business Expect Strong Rebound in Growth Revenue Performance (In ₹ Crore) ❖ Inhalation Anesthesia – Maintain leadership in the US, Expand in ex-US markets 3% 7% • US - Growing ahead of the market; #1 in Sevoflurane with 47% value share (up from 45% in Mar’24). (Source:- IQV
Slide 22: Complex Hospital Generics Business
Complex Hospital Generics Business ❖ Completed Kenalog® Acquisition – Adds new lever of growth • Transaction - US$35Mn upfront plus up to US$65Mn contingent considerations. • Broadens CHG portfolio, adds revenues with minimal incremental cost, and expands presence in US, Europe & Asia Pacific. • Exp
Slide 23: CHG Revenues by Product Segment and Geography
CHG Revenues by Product Segment and Geography Revenue by Product Segment Revenue by Geography % FY26 CHG Revenue Inhalation Anesthesia Intrathecal Therapy Others 21% (64%) (15%) US India 6% FY26 CHG 51% Revenue Japan 6% Injectable Anesthesia and Other Speciality Products Pain Management (11%) (10%)
Slide 24: Inhalation Anesthesia - #1 in the US, Expanding in ex-US Markets
Inhalation Anesthesia - #1 in the US1, Expanding in ex-US Markets Our Strengths Our Market Standing Vertical Integration – Better Control on Cost and Supply Chain Leading Player in Sevoflurane in the US KSM Sevoflurane and Sevoflurane and Manufacturing Desflurane Isoflurane Dahej, India Bethlehem, US Di
Slide 25: Niche and Branded Portfolio with Limited Competition
Niche and Branded Portfolio with Limited Competition Intrathecal Therapy Injectable Pain Management Maintain our Leadership Position1 in the US Strengthening Supply Chains to Capture Market Demand • Established Brands with Leading Market Share • Established Brands with Leading Market Share – Brand #
Slide 26: Piramal Consumer Healthcare Business
Piramal Consumer Healthcare Business Expect Growth Momentum to Continue Revenue Performance (In ₹ Crore) ❖ Delivered strong growth of 17% in FY26 – higher than market growth rate. 17% 17% ❖ Power Brands – Build Brand Equity to Achieve Scale • Contributing 52% to total PCH sales in FY26 (vs. 42% in F
Slide 27: Piramal Consumer Healthcare Business
Piramal Consumer Healthcare Business Portfolio ❖ Continuous Investments in Media & Trade Promotion – Build Brand Equity; Drive Customer Pull Premiumization • Invested about 12% of PCH sales on Media and Trade Promotion in FY26. • Optimizing the media mix – Social Media, Television, Influencers, etc.
Slide 28: Continuous Investments in Media and Trade Promotion
Continuous Investments in Media and Trade Promotion… (In ₹ Cr) Investments in Brand Promotion and Marketing % of PCH 15% 13% 11% 12% sales 148 131 131 125 Effie Award for Integrated Campaign Lacto Calamine OMD Sunscreen Mcanvas Campaign: Excellence: Honoured for i-pill Daily at Effie Awarded for Mos
Slide 29: Driving Growth in Power Brands
…Driving Growth in Power Brands… (In ₹ Cr) Strong Growth in our Power Brands 22% CAGR 664 448 538 370 FY23 FY24 FY25 FY26 Increasing Contribution of Power Brands 45% 49% 52% 42% FY23 FY24 FY25 FY26 29
Slide 30: Financials
Financials
Slide 31: Consolidated Financials Highlights
Consolidated Financials Highlights (in ₹ Cr. or as stated) Particulars Q4FY26 Q4FY25 YoY Change Q3FY26 QoQ Change FY26 FY25 YoY Change Revenue from Operations1 2,752 2,754 (0)% 2,140 29% 8,869 9,151 (3)% CDMO 1,708 1,788 (4)% 1,166 47% 4,915 5,447 (10)% CHG 755 705 7% 668 13% 2,703 2,633 3% PCH 320
Slide 32: Consolidated Financials Highlights
Consolidated Financials Highlights (in ₹ Cr.) Key Balance Sheet Items As on 31-Mar-26 As on 31-Mar-25 Total Equity 8,162 8,125 Net Debt 4,140 4,199 Total 12,302 12,324 Net Fixed Assets 9,784 9,110 Tangible Assets 4,843 4,534 Intangible Assets including goodwill 3,841 3,599 CWIP (including IAUD1) 1,1
Slide 33: Dial-in Details for Q4 and Full-year FY26 Earnings Conference Call
Dial-in Details for Q4 and Full-year FY26 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 09:30 AM IST 1 800 120 1221 (Toll free number) USA – 12:00 AM Toll free number Conference call on (Eastern Time – New York) 186674621
Slide 34: For Investor Queries
For Investor Queries: Gagan Borana Madhusudan Dalmia Investor Relations and Enterprise Risk Management Investor Relations Email: gagan.borana@piramal.com Email: madhusudan.dalmia@piramal.com Our Websites:- Piramal Pharma Limited CDMO www.piramalpharma.com www.piramalpharmasolutions.com Complex Hospi